An overview of Semglee and why it is authorised in the EU
Semglee is a medicine used to treat diabetes in patients from 2 years of age. It contains the active substance insulin glargine.
Semglee : EPAR - Medicine overview (PDF/105.93 KB)
First published: 23/05/2018
Last updated: 23/05/2018
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
|Date of issue of marketing authorisation valid throughout the European Union||
03/04/2018 Semglee - EMEA/H/C/004280 - IB/0002
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Drugs used in diabetes
Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.